The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 400 currently available and novel biosimilar products, detailing information about the region(s) and their clinical phase of development. Additionally, we provide estimates for biosimilar launches in the seven major markets (United States, EU5, and Japan), as well as aggregate statistics to help answer key competitive intelligence questions. The Emerging Biosimilars Landscape is updated quarterly.

Questions Answered in This Report:

  • How many biosimilar candidates are currently undergoing phase I or III clinical development in a particular region?
  • Which biologic classes and reference molecules are most frequently targeted by biosimilars developers?
  • Which are the top 10 biosimilars developers by number of clinical stage candidates?
  • When is the expected launch date for late stage pipeline candidates in the seven major markets?
  • What is the level of competition expected for a brand, globally and by region/country?

Scope:

  • Markets covered: Global
  • Secondary research: clinical trial registries, company pipelines, annual reports, news articles, company press releases and presentations.

Mentioned in This Report:

Key Companies Mentioned

  • Amgen
  • Biocad
  • Biocon
  • Celltrion
  • Daiichi Sankyo
  • Dr. Reddy's
  • Fresenius Kabi
  • Gedeon Richter
  • Intas
  • Merck & Co
  • Mylan
  • Pfizer
  • Samsung Bioepis
  • Sandoz
  • Stada

Key Drugs Mentioned

  • Aranesp
  • Avastin
  • Enbrel
  • Erbitux
  • Forteo
  • Herceptin
  • Humira
  • Lantus
  • Neulasta
  • Neupogen
  • Remicade
  • Rituxan / MabThera

Table of contents

  • Emerging Biosimilars Landscape
    • Biosimilars Pipeline Analysis
      • Biosimilars Development Pipeline by Phase of Development
      • Biosimilars Development Pipeline by Class
      • Biosimilars Development Projects by Reference Molecule
      • Leading Biosimilars Developers
      • Biosimilar Launch Dates
    • Appendix
      • Methodology

Author(s): Hamzah Aideed, MSc

Hamzah Aideed is a Principal Analyst in the biosimilars team at Decision Resources Group. Hamzah’s responsibilities include conducting primary and secondary market research, generating key insights into biosimilars and the biopharmaceutical industry, and providing client support. His work in biosimilars encompasses four key therapy areas – immunology, oncology, endocrinology, and nephrology. Prior to joining DRG, Hamzah was a Senior Research Executive at Consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies, for bespoke ad-hoc consulting projects. He holds an in Biotechnology & Business Management from the University of Warwick and a in Biological Chemistry from Aston University.